What is BioCircuit Technologies?
BioCircuit Technologies is at the forefront of developing and commercializing cutting-edge medical devices designed for tissue repair and neuromodulation. Their flagship innovation, Nerve Tape®, holds the distinction of being the first FDA-cleared sutureless device engineered for repairing transected nerves. This technology significantly enhances surgical efficiency and minimizes tissue damage, aiming to equip healthcare professionals with superior tools for diagnosing and treating nerve injuries across various medical disciplines. The company's focus on plastic and reconstructive surgery highlights its commitment to streamlining nerve repair procedures and improving patient outcomes.
How much funding has BioCircuit Technologies raised?
BioCircuit Technologies has raised a total of $9M across 1 funding round:
Angel/Seed
$9M
Angel/Seed (2022): $9M with participation from Masters Capital Management and GRA Venture Fund
Key Investors in BioCircuit Technologies
Masters Capital Management
Masters Capital Management is an investment adviser specializing in US equities and listed equity options, aiming to deliver long-term absolute returns. Their involvement suggests a strategic financial backing for BioCircuit Technologies' growth.
GRA Venture Fund
GRA Venture Fund is a public-private venture capital fund that invests in research-driven startup companies based in Georgia, focusing on science and technology enterprises. Their participation indicates confidence in BioCircuit Technologies' innovative medical device platform.
What's next for BioCircuit Technologies?
The recent major strategic investment positions BioCircuit Technologies for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, scale manufacturing capabilities, and expand commercialization efforts for Nerve Tape® and other pipeline innovations. The company's focus on addressing critical unmet needs in nerve repair suggests a trajectory towards becoming a leader in the medical device industry, with potential for further strategic partnerships and market expansion into related therapeutic areas.
See full BioCircuit Technologies company page
